Taming the Heart Risks of Revolutionary Cancer Immunotherapy

Immune checkpoint inhibitors (ICIs) have significantly advanced cancer therapy, yet they carry a risk of disrupting immune self-tolerance. This can lead to immune checkpoint inhibitor-related myocarditis (ICIrM), a condition associated with high mortality rates where the immune system inadvertently attacks heart tissue. Because the clinical presentation ranges widely—from asymptomatic changes in blood markers to fulminant heart failure—uniform treatment guidelines are often insufficient.

Experts argue that a personalised approach is essential for patient safety. Diagnosis relies on sensitive tools, such as cardiac MRI and the monitoring of cardiac troponins (proteins that indicate heart injury). Furthermore, measuring global longitudinal strain via echocardiogram offers a more sensitive risk assessment than traditional methods.

Once confirmed, the cornerstone of therapy remains high-dose corticosteroids to suppress the immune response. In severe or steroid-refractory cases, clinicians may utilise adjunctive immunomodulators like abatacept, which is currently being investigated in a randomised trial. As research continues, the focus is on refining these diagnostic algorithms to ensure cancer patients survive the cure.